Scientific Industries Inc (OTC: SCND)

Scientific Industries Inc designs, manufactures, and markets standard benchtop laboratory equipment and bioprocessing systems. The company operates in the scientific equipment industry, catering primarily to research purposes across various sectors. Scientific Industries Inc was incorporated in 1954 and has since established itself as a key player in the laboratory equipment market.

The company generates revenue through the sale of its benchtop laboratory equipment and bioprocessing systems. Its primary products include mixers and shakers, rotators/rockers, refrigerated and shaking incubators, magnetic stirrers, pharmacy and laboratory balances and scales, force gauges, automated pill counters, moisture analyzers, and bioprocessing products incorporating smart sensors and state-of-the-art software analytics. These products are sold to universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, and other industries performing laboratory-scale research. The Vortex-Genie 2 Mixer is a significant revenue driver, accounting for approximately 33% and 32% of the company's total net revenues for the years ended December 31, 2024 and 2023, respectively.

• Benchtop Laboratory Equipment: This segment includes various types of equipment used for research and sample preparation in university, pharmacy, and industrial laboratories. Key products under this segment include the Genie brand mixers and shakers, rotators/rockers, refrigerated and shaking incubators, and magnetic stirrers. The Torbal division offers pharmacy and laboratory balances and scales, force gauges, automated pill counters, and moisture analyzers. These products are primarily sold through laboratory equipment distributors and online platforms. The Vortex-Genie 2 Mixer is a flagship product, contributing significantly to the company's revenue. The segment also includes the VIVID brand automated pill counters, which are sold through exclusive distributors in North America.

• Bioprocessing Systems: This segment focuses on the design, development, manufacture, and marketing of bioprocessing products. Key products include the Cell Growth Quantifier (CGQ) for biomass monitoring in shake flasks, the Liquid Injection System (LIS) for automated feeding in shake flasks, and a line of coaster systems and flow-through cells for pH and DO monitoring and analytical software. The Multi-Parameter Sensor (MPS) and Dissolved Oxygen sensor pills are marketed under the Bioprocessing Systems DOTS brand platform. These products are sold primarily on a direct basis through the company's internal sales force and a network of distributors.

Scientific Industries Inc competes in a market dominated by larger players with greater financial, production, and marketing resources. Key competitors for its Genie brand benchtop laboratory equipment include Henry Troemner, Inc., IKA-Werke GmbH & Co. KG, Benchmark Scientific, Inc., and Heidolph Instruments GmbH. For its Torbal brand products, main competitors are Ohaus Corporation, A&D Company Ltd., Adam Equipment Co., Ltd., Avery Weigh-Tronix, and Capsa Healthcare. In the bioprocessing systems market, direct competitors include ABER Instruments and PreSens GmbH, while indirect competitors include Hamilton Bonaduz AG, optek-Danulat GmbH, Sartorius AG, and Eppendorf SE. The company's competitive advantages lie in its proprietary trademarks, patents, and ongoing investment in research and development, particularly in the bioprocessing systems segment.

The company's customer base is diverse, including universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, and other industries performing laboratory-scale research. Sales to the three top customers, principally of the Vortex-Genie 2 Mixer, represented 15% and 16% of consolidated net revenues for the years ended December 31, 2024 and 2023, respectively. The company's products are sold both domestically and internationally, with overseas customers, principally in Asia and Europe, accounting for approximately 39% and 34% of the company's net revenue for the year ended December 31, 2024 and 2023, respectively.